Oragenics to Network at SCOPE Summit Ahead of Concussion Trial
Event summary
- Oragenics will participate in the SCOPE Summit 2026, February 2–5 in Orlando, Florida.
- The company aims to engage with clinical research leaders before commencing Phase 2a trials of ONP-002 in Australia.
- SCOPE Summit attracts over 1,200 companies from 30 countries, focusing on clinical operations and innovation.
- ONP-002 is a lead candidate targeting concussion and mild traumatic brain injury, a market with significant unmet need.
The big picture
The SCOPE Summit represents a key networking opportunity for Oragenics as it advances its lead candidate for concussion treatment. The company's focus on intranasal delivery for neurological disorders positions it within a growing area of therapeutic innovation, but clinical trial success remains the critical determinant of long-term value. The summit's emphasis on generative AI and RBQM suggests a broader industry shift towards data-driven clinical operations, which Oragenics will need to adapt to.
What we're watching
- Trial Execution
- The value of Oragenics' participation in SCOPE hinges on whether they can glean actionable insights to optimize the Phase 2a trial design and execution, given the complexity of neurological research.
- Regulatory Pathway
- The success of ONP-002 will depend on navigating regulatory hurdles, and the company's engagement with regulatory affairs experts at SCOPE could signal an attempt to proactively address potential challenges.
- Competitive Landscape
- The summit provides an opportunity to assess the competitive landscape for concussion treatments and gauge the perceived differentiation of Oragenics' intranasal delivery platform.
Related topics